Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Vaxcyte, Inc. (PCVX)

Caris Life Sciences,�Inc. and Vaxcyte, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Vaxcyte, Inc. are of similar size ($9.8B and $9.7B). Vaxcyte, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 86.1×. Caris Life Sciences,�Inc. has the higher net margin (10.6% vs 0.00%) and the higher return on invested capital (50.0% vs −57.3%). Across the 14 metrics below, Caris Life Sciences,�Inc. leads on 11 and Vaxcyte, Inc. on 3.

Valuation

Metric CAI PCVX Biotechnology median
P/E 86.06 n/m 10.71
P/S 9.25 n/m 9.84
P/B 15.47 3.18 2.15
Price to free cash flow 73.83 n/m 25.78
EV/EBITDA 48.62 n/m 0.65
EV/Sales 8.84 n/m 9.47
Earnings yield 1.16% (12.55%) (34.53%)
Free cash flow yield 1.35% (10.18%) (24.00%)

Profitability

Metric CAI PCVX Biotechnology median
Gross margin 69.66% 0.00% 69.20%
Operating margin 15.49% 0.00% 0.00%
Net margin 10.62% 0.00% 0.00%
Free cash flow margin 12.53% 0.00% 0.00%
Return on equity 20.13% (36.51%) (53.10%)
Return on assets 9.62% (33.03%) (46.06%)
Return on invested capital 49.95% (57.30%) 0.00%

Growth

Metric CAI PCVX Biotechnology median
Revenue growth (TTM) 96.36% — 5.26%
EPS growth (last fiscal year) 69.79% (48.16%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI PCVX Biotechnology median
Debt to equity 0.66 0.00 0.00
Current ratio 5.53 5.72 4.98
Net debt to EBITDA (5.23) 1.71 1.01

Dividend

Metric CAI PCVX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CAI PCVX Biotechnology median
Market cap 9.70b 9.76b 171.46m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack